38 results on '"Rodriguez-Salas N"'
Search Results
2. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review
3. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy
4. Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review
5. Carcinoma de células de Merkel: diagnóstico y tratamiento en atención especializada dermatológica. Guía de práctica clínica de la Academia Española de Dermatología y Venerología
6. 382P Sequential RAS mutation status evaluation in circulating free DNA (cfDNA) in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) starting first-line (1L) treatment with panitumumab (P) and chemotherapy (CT). PERSEIDA (Idylla Cohort) study
7. Clinical guideline SEOM: hepatocellular carcinoma
8. 455P Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
9. Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial
10. P-279 Adjuvant chemotherapy for patients with stage III colon cancer, three months vs six months. A single centre experience
11. P-265 Value of the Glasgow Prognostic Score (GPS) in the prognosis of hospitalised patients with gastrointestinal cancer
12. P-261 Oxaliplatine plus fluoropyrimidine versus fluoropyrimidine monotherapy as adjuvant treatment for stage III resected colorectal cancer (CRC) in older population, a single centre experience
13. P-242 Characterisation of KRAS mutations in patients with metastatic colorectal cancer: A single institution experience
14. P-222 Prognostic value of skeletal muscle area at diagnosis in patients with metastatic colorectal cancer: A single institution experience
15. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy
16. Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review
17. P-87 Clinical score to predict recurrence in patients with stage II and III colon cancer
18. P-41 What to expect from best supportive care as initial approach for newly-diagnosed colorectal cancer: A single institution experience
19. P-40 Clinico-pathological characteristics and outcomes of patients with early-onset colorectal cancer
20. P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification
21. P-84 Genotype-fenotype correlation in patients with Lynch syndrome and colorectal cancer
22. Pregnancy in a breast cancer patient treated with a LHRH analogue at ablative doses
23. Clinical and pathological features in colorectal cancer associated to Lynch syndrome
24. Retrospective analysis of clinical factors associated with a greater benefit with Trifluridine and Tipiracil in metastasic colorectal cancer
25. Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study
26. P-315 - ΔNp73 and Δ133p53 in liquid biopsy as early diagnostic markers for colorectal cancer
27. P-190 - Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients
28. P-191 - Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)
29. P-276 - Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study
30. P-266 - Retrospective analysis of clinical factors associated with a greater benefit with Trifluridine and Tipiracil in metastasic colorectal cancer
31. P-236 - Clinical and pathological features in colorectal cancer associated to Lynch syndrome
32. Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas
33. 9P Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study.
34. Cancer predisposing syndrome: a retrospective cohort analysis in a pediatric and multidisciplinary genetic cancer counseling unit.
35. Clinical and pathological features of Merkel cell carcinoma: A 4-year follow-up observational retrospective study in Spain.
36. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.
37. Clinical relevance of colorectal cancer molecular subtypes.
38. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.